{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:32:42Z","timestamp":1786984362367,"version":"build-2736575974"},"reference-count":9,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.amjmed.2020.03.054","type":"journal-article","created":{"date-parts":[[2020,5,13]],"date-time":"2020-05-13T08:50:46Z","timestamp":1589359846000},"page":"e716-e721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9805-4562","authenticated-orcid":false,"given":"Anthony P.","family":"Carnicelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Lena","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brooke","family":"Alhanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7480-3656","authenticated-orcid":false,"given":"Magnus","family":"Bjursell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Perl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Lytle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew T.","family":"Roe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.amjmed.2020.03.054_bib0001","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.054_bib0002","doi-asserted-by":"crossref","DOI":"10.1152\/ajpheart.00533.2015","article-title":"Relationship of hyperuricemia with mortality in heart failure patients with preserved ejection fraction","volume":"309","author":"Shimizu","year":"2015","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"7","key":"10.1016\/j.amjmed.2020.03.054_bib0003","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.amjcard.2017.06.057","article-title":"Prevalence of hyperuricemia in patients with acute heart failure with either reduced or preserved ejection fraction","volume":"120","author":"Palazzuoli","year":"2017","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.amjmed.2020.03.054_bib0004","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3909\/ricm0889","article-title":"Hyperuricemia and cardiovascular disease","volume":"18","author":"Palazzuoli","year":"2017","journal-title":"Rev Cardiovasc Med"},{"issue":"5","key":"10.1016\/j.amjmed.2020.03.054_bib0005","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/CIRCRESAHA.118.312706","article-title":"Established and emerging roles of biomarkers in heart failure","volume":"123","author":"Ibrahim","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.amjmed.2020.03.054_bib0006","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ahj.2017.02.023","article-title":"An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndrome","volume":"187","author":"Pagidipati","year":"2017","journal-title":"Am Heart J"},{"issue":"16","key":"10.1016\/j.amjmed.2020.03.054_bib0007","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.118.009328","article-title":"Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease","volume":"7","author":"Pagidipati","year":"2018","journal-title":"J Am Heart Assoc"},{"issue":"20","key":"10.1016\/j.amjmed.2020.03.054_bib0008","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1161\/CIRCULATIONAHA.114.014536","article-title":"Effects of xanthine oxidase inhibition in hyperuricemic heart failure patients: the xanthine oxidase inhibition for hyperuricemic heart failure patients (EXACT-HF) study","volume":"131","author":"Givertz","year":"2015","journal-title":"Circulation"},{"issue":"8 suppl","key":"10.1016\/j.amjmed.2020.03.054_bib0009","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1016\/j.cardfail.2019.07.071","article-title":"Uric-acid lowering treatment by a xanthine oxidase inhibitor improved the diastolic function in patients with hyperuricemia","volume":"25","author":"Ogino","year":"2019","journal-title":"J Card Fail"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303703?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934320303703?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T09:20:58Z","timestamp":1757582458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934320303703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":9,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0002934320303703"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.054","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated Uric Acid Prevalence and Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: Insights from RELAX","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2020.03.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}